CN105163726A - 治疗萎缩症或增加细胞生长的药物 - Google Patents

治疗萎缩症或增加细胞生长的药物 Download PDF

Info

Publication number
CN105163726A
CN105163726A CN201380072269.4A CN201380072269A CN105163726A CN 105163726 A CN105163726 A CN 105163726A CN 201380072269 A CN201380072269 A CN 201380072269A CN 105163726 A CN105163726 A CN 105163726A
Authority
CN
China
Prior art keywords
cell
serf2
cells
nucleic acid
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380072269.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·贝格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIMU TRADE CONSULTING & CO LEASING KG GmbH
Original Assignee
SIMU TRADE CONSULTING & CO LEASING KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIMU TRADE CONSULTING & CO LEASING KG GmbH filed Critical SIMU TRADE CONSULTING & CO LEASING KG GmbH
Publication of CN105163726A publication Critical patent/CN105163726A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201380072269.4A 2012-12-14 2013-12-13 治疗萎缩症或增加细胞生长的药物 Pending CN105163726A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197192.3 2012-12-14
EP12197192.3A EP2742935A1 (en) 2012-12-14 2012-12-14 SERF2 for the treatment of atrophy and for increasing cell growth
PCT/EP2013/076547 WO2014090991A1 (en) 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth

Publications (1)

Publication Number Publication Date
CN105163726A true CN105163726A (zh) 2015-12-16

Family

ID=47355920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380072269.4A Pending CN105163726A (zh) 2012-12-14 2013-12-13 治疗萎缩症或增加细胞生长的药物

Country Status (7)

Country Link
US (2) US9637529B2 (enExample)
EP (2) EP2742935A1 (enExample)
JP (1) JP2016508123A (enExample)
CN (1) CN105163726A (enExample)
AU (1) AU2013357283A1 (enExample)
CA (1) CA2895131A1 (enExample)
WO (1) WO2014090991A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022884A (zh) * 2016-11-30 2019-07-16 白雁生物技术公司 含有线粒体的药物组合物
CN118108828A (zh) * 2022-11-29 2024-05-31 上海众启生物科技有限公司 含有serf2的蛋白抗原组合及其应用
WO2025148411A1 (zh) * 2024-01-09 2025-07-17 上海众启生物科技有限公司 一种用于阿尔茨海默症检测的蛋白抗原组合及应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120127543A (ko) 2008-05-23 2012-11-21 시와 코퍼레이션 재생을 촉진하는 방법, 조성물 및 장치
RU2721568C2 (ru) 2014-09-19 2020-05-20 Сива Корпорейшн Анти-age антитела для лечения воспаления и аутоиммунных нарушений
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
CN109071675A (zh) 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3475306A1 (en) 2016-06-23 2019-05-01 Siwa Corporation Vaccines for use in treating various diseases and disorders
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN113337460A (zh) * 2021-06-10 2021-09-03 呼和浩特职业学院 一种绵羊骨骼肌卫星细胞的高效分离和纯化方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
EP1572987A4 (en) * 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHARF JM ET AL: "dentification of a candidate modifying gene for spinal muscular atrophy by comparative genomics", 《NAT GENET》 *
SCHARF JM ET AL: "NM_001018108，Homo sapiens small EDRK-rich factor2(SERF2),mRNA", 《NCBI GENBANK》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022884A (zh) * 2016-11-30 2019-07-16 白雁生物技术公司 含有线粒体的药物组合物
CN118108828A (zh) * 2022-11-29 2024-05-31 上海众启生物科技有限公司 含有serf2的蛋白抗原组合及其应用
WO2024114615A1 (zh) * 2022-11-29 2024-06-06 上海众启生物科技有限公司 含有serf2的蛋白抗原组合及其应用
CN118108828B (zh) * 2022-11-29 2025-10-28 上海众启生物科技有限公司 含有serf2的蛋白抗原组合及其应用
WO2025148411A1 (zh) * 2024-01-09 2025-07-17 上海众启生物科技有限公司 一种用于阿尔茨海默症检测的蛋白抗原组合及应用

Also Published As

Publication number Publication date
WO2014090991A1 (en) 2014-06-19
EP2931264A1 (en) 2015-10-21
AU2013357283A1 (en) 2015-07-09
US20170253641A1 (en) 2017-09-07
CA2895131A1 (en) 2014-06-19
JP2016508123A (ja) 2016-03-17
US9637529B2 (en) 2017-05-02
EP2742935A1 (en) 2014-06-18
US20150307568A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
CN105163726A (zh) 治疗萎缩症或增加细胞生长的药物
JP2022065004A (ja) ミトコンドリアを含む医薬組成物
Klettner et al. Basal and apical regulation of VEGF-A and placenta growth factor in the RPE/choroid and primary RPE
CN102076351A (zh) 损伤组织的功能性再生促进药物
WO2011052668A1 (ja) 骨髄間葉系および/または多能性幹細胞の血中動員による組織再生促進剤
CN111417718B (zh) 由cd31阳性cd45阴性cd200阳性的哺乳动物细胞组成的细胞群及其应用
WO2016125330A1 (ja) 網膜再生促進薬
US11622964B2 (en) Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof
US20160206699A1 (en) Use of interleukin 10 mrna transfected macrophages in anti-inflammatory therapies
CN101316584A (zh) 用于预防及治疗由血管通透性亢进引起的眼病的医药
Baiersdörfer et al. Toll-like receptor 3 mediates expression of clusterin/apolipoprotein J in vascular smooth muscle cells stimulated with RNA released from necrotic cells
CN106148276A (zh) 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
JP2015524402A (ja) 創傷治療用の薬剤
Trofimova Molecular mechanisms of retina pathology and ways of its correction
JP6397122B2 (ja) 血管新生関連疾患を治療するためのペプチドの使用
KR20220066959A (ko) 생체 조직 손상 수복제의 제조 방법 및 생체 조직 손상 수복제
CN118831152A (zh) 导管素抗菌肽在缺血性脑卒中药物中的应用
CN105194653B (zh) 锌指蛋白307（znf307）在治疗心肌肥厚中的应用
CN107034217A (zh) 启动子、重组间质干细胞及其制备方法和应用
CN108721314A (zh) 化合物epz5676及其相关抑制剂在制备防治肺纤维化疾病药物中的用途
US20240181125A1 (en) Compositions and methods for scarless wound healing in diabetes
Soliman et al. Platelet-Rich Plasma Attenuates Isoproterenol-Induced Myocardial Injury in Adult Male Albino Rat: Histological and Immunohistochemical Study
CN112569338B (zh) Tdfa在制备预防和/或治疗眼表炎症疾病的药物中的应用
TW201822813A (zh) 腦梗塞的治療藥
Dabouz Neuro-immune interactions in age-related macular degeneration: implications for future therapeutics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151216